These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 3147888)

  • 21. Comparative in vitro activities of norfloxacin (MK-0366) and six commonly used antimicrobial agents against 199 urinary isolates showing various degrees of antibiotic resistance.
    Corigliano BE; Appleman MD; Heseltine PN; Leedom JM
    Diagn Microbiol Infect Dis; 1984 Apr; 2(2):101-6. PubMed ID: 6232085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [In-vivo bacteriostatic and bactericidal activity of pefloxacine].
    Meyran M; Thabaut A
    Pathol Biol (Paris); 1986 May; 34(5):349-52. PubMed ID: 3095772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Susceptibility testing of urinary tract pathogens to norfloxacin.
    Andrews JM; Wise R
    J Antimicrob Chemother; 1991 Aug; 28(2):309-11. PubMed ID: 1778861
    [No Abstract]   [Full Text] [Related]  

  • 24. New norfloxacin resistance gene in Pseudomonas aeruginosa PAO.
    Fukuda H; Hosaka M; Hirai K; Iyobe S
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1757-61. PubMed ID: 2126688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin.
    Zeiler HJ
    Drugs Exp Clin Res; 1985; 11(5):335-8. PubMed ID: 2941261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance in critically ill medical patients.
    Martínez JA; Delgado E; Martí S; Marco F; Vila J; Mensa J; Torres A; Codina C; Trilla A; Soriano A; Alquezar A; Castro P; Nicolás JM
    Intensive Care Med; 2009 Mar; 35(3):439-47. PubMed ID: 18936910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Norfloxacin treatment in complicated urinary tract infection.
    Boerema JB; van Saene HK
    Scand J Infect Dis Suppl; 1986; 48():20-6. PubMed ID: 3465030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complicated urinary tract infection caused by Pseudomonas aeruginosa in a single institution (1999-2003).
    Shigemura K; Arakawa S; Sakai Y; Kinoshita S; Tanaka K; Fujisawa M
    Int J Urol; 2006 May; 13(5):538-42. PubMed ID: 16771722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparative bacteriologic activity of norfloxacin, ofloxacin and pefloxacin against 320 Gram-negative bacilli resistant and non-resistant to nalidixic acid and cephalosporins].
    Croize J; Le Noc P; Bryskier A; Robert J
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):564-8. PubMed ID: 3937128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Susceptibility of Pseudomonas aeruginosa to fluoroquinolones following four years of use in a tertiary care hospital.
    Shalit I; Haas H; Berger SA
    J Antimicrob Chemother; 1992 Aug; 30(2):149-52. PubMed ID: 1399924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. N-formimidoyl-thienamycin and norfloxacin against multiple-resistant Pseudomonas aeruginosa strains. Combined in vitro activity and comparison with 14 other antibiotics.
    Martino P; Venditti M; Valente B; Brandimarte C; Serra P
    Drugs Exp Clin Res; 1985; 11(4):247-51. PubMed ID: 3939121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
    Pfaller MA; Bassetti M; Duncan LR; Castanheira M
    J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Development of resistance in imipenem therapy in Pseudomonas aeruginosa].
    Krech T; Naumann P
    Immun Infekt; 1986 Nov; 14(6):224-6. PubMed ID: 3100426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [In vivo-acquired resistance to cefsulodin by a strain of Pseudomonas aeruginosa].
    Jouvenot M; Michel-Briand Y; Dupont MJ; Cattin J
    Pathol Biol (Paris); 1984 May; 32(5):426-8. PubMed ID: 6429615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inducible beta-lactamases in clinical isolates of non-aeruginosa Pseudomonas.
    Ravaoarinoro M; Toma E; Fallara A
    APMIS; 1992 Jun; 100(6):523-30. PubMed ID: 1610551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Norfloxacin versus trimethoprim-sulfamethoxazole in the treatment of urinary tract infections.
    Corrado ML; Hesney M; Struble WE; Brown KR; Eng RH; Landes R; Harrison L; Ryan J; Bolding OT
    Eur Urol; 1990; 17 Suppl 1():34-9. PubMed ID: 2191867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined topical use of silver sulfadiazine and antibiotics as a possible solution to bacterial resistance in burn wounds.
    Modak SM; Sampath L; Fox CL
    J Burn Care Rehabil; 1988; 9(4):359-63. PubMed ID: 3146573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
    Hernández-Tejedor A; Merino-Vega CD; Martín-Vivas A; Ruiz de Luna-González R; Delgado-Iribarren A; Gabán-Díez Á; Temprano-Gómez I; de la Calle-Pedrosa N; González-Jiménez AI; Algora-Weber A
    Infection; 2017 Feb; 45(1):115-117. PubMed ID: 27670678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efflux pump genes and antimicrobial resistance of Pseudomonas aeruginosa strains isolated from lower respiratory tract infections acquired in an intensive care unit.
    Ozer B; Duran N; Onlen Y; Savas L
    J Antibiot (Tokyo); 2012 Jan; 65(1):9-13. PubMed ID: 22086166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.